Found: 2
Select item for more details and to access through your institution.
Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis.
- Published in:
- Rheumatology, 2022, v. 61, n. 4, p. 1385, doi. 10.1093/rheumatology/keab460
- By:
- Publication type:
- Article
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.
- Published in:
- Arthritis Research & Therapy, 2021, v. 23, n. 1, p. 1, doi. 10.1186/s13075-020-02394-7
- By:
- Publication type:
- Article